Estrogen levels in premenopausal (prem) patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy.
Meritxell Bellet
No relevant relationships to disclose
Kathryn P. Gray
No relevant relationships to disclose
Prudence A. Francis
No relevant relationships to disclose
Istvan Lang
No relevant relationships to disclose
Eva Ciruelos
No relevant relationships to disclose
Ana Lluch
No relevant relationships to disclose
Miguel Angel Climent
Consultant or Advisory Role - Pfizer
Gustavo Catalan
No relevant relationships to disclose
Roser Ferrer Costa
No relevant relationships to disclose
Roberto Catalan
No relevant relationships to disclose
Agnita Rajasekaran
No relevant relationships to disclose
Josefa Morales
No relevant relationships to disclose
Josep Vazquez
No relevant relationships to disclose
Gini F. Fleming
No relevant relationships to disclose
Karen N. Price
No relevant relationships to disclose
Meredith M. Regan
No relevant relationships to disclose